

**DEPARTMENT OF HEALTH AND HUMAN SERVICES  
FOOD AND DRUG ADMINISTRATION**

DISTRICT ADDRESS AND PHONE NUMBER 10903 New Hampshire Avenue, Building 51, Room 4225, Silver Spring, MD 20993-0002 Phone: (301) 796-3334. Fax: (301) 847-8738 Industry Information: <a href="http://www.fda.gov/oc/industry">www.fda.gov/oc/industry</a>		DATE(S) OF INSPECTION 12/07/2016-12/16/2016*
		FEI NUMBER 3008307735
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED <b>TO: Mr. Pabbati Reddy Bhaskar Reddy, Vice President Operations</b>		
FIRM NAME <b>Hetero Labs Limited</b>	STREET ADDRESS <b>TSIIC Pharma SEZ</b>	
CITY, STATE, ZIP CODE, COUNTRY <b>Polepally Village, Jadcherla Mandal, Mahaboob Nagar District, Telangana State, 509301, India</b>	TYPE ESTABLISHMENT INSPECTED <b>Oral Solid Dose Drug Product Manufacturer</b>	

This document lists observations made by the FDA representatives during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection or action with the FDA representatives during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above.

**DURING AN INSPECTION OF YOUR FIRM WE OBSERVED:**

**OBSERVATION 1**

The responsibilities and procedures applicable to the quality control unit are not fully followed.

(1) Specifically, your QA technicians and other individuals were recorded destroying and altering records pertaining to commercial batch manufacturing immediately prior to this regulatory inspection. The loss of data and documents are evidenced by the following:

Through a review of your firms Closed Circuit TV we identified the following:

- (a) A document shredder was introduced into your firm's "DOCUMENTS STORAGE AREA" on December 03, 2016 at 15:44, approximately 4 days prior to the current US FDA inspection.
- (b) After introduction of the document shredder we observed extensive shredding of what appears to be controlled documents and extensive signing of documents by QA. These documents were of a color consistent with batch packaging records and batch manufacturing records, among other documents. Your firm failed to maintain documentation of what had been shredded.
- (c) On December 06, 2016, at <sup>(b) (4)</sup> we observed that a contract employee with QA removed documents from the shredder and placed them in his pocket.
- (d) On December 07, 2016, at approximately 1:13 (in the middle of the night) individuals were shredding documents. Your firm stated this event represented cleaning staff shredding documents.

SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE Massoud Motamed, Investigator Latorie S. Jones, Investigator <i>[Handwritten signatures of Massoud Motamed and Latorie S. Jones]</i>	DATE ISSUED 12/16/2016
--------------------------	---	---------------------------